Harmony Biosciences Holdings, Inc. (HRMY)

Market Cap	2.50B +17.6%
Revenue (ttm)	959.90M +24.3%
Net Income	181.27M +0.2%
EPS	3.09 -0.1%
Shares Out	58.24M
PE Ratio	13.87
Forward PE	10.70
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,111,960
Open	41.31
Previous Close	41.25
Day's Range	41.25 - 43.02
52-Week Range	25.52 - 43.02
Beta	0.91
Analysts	Buy
Price Target	47.36 (+10.5%)
Earnings Date	Aug 4, 2026

About HRMY

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in P...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 19, 2020
• Employees: 293
• Stock Exchange: NASDAQ
• Ticker Symbol: HRMY
• Website: https://www.harmonybiosciences.com

Financial Performance

In 2025, HRMY's revenue was $868.45 million, an increase of 21.51% compared to the previous year's $714.73 million. Earnings were $158.69 million, an increase of 9.07%.

Analyst Summary

According to 11 analysts, the average rating for HRMY stock is "Buy." The 12-month stock price target is $47.36, which is an increase of 10.50% from the latest price.

Price Target

$47.36

(10.50% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 3, 2026

Data Sources Report a data error